Optimizing Treatment of Resistant/Refractory CMV Infection in Solid Organ Transplant Recipients

Program Overview

CMV is one of the most common opportunistic infections affecting solid organ transplant recipients (SOTRs), conveying higher risks of complications, graft loss, morbidity, and mortality. Treatment options for CMV are limited, have similar mechanisms of action, suffer from cross-resistance, and have serious toxicities. Until recently, no treatment option was available in the resistant/refractory setting. This workshop, developed in collaboration with The Transplantation Society (TTS) and Dr. Camille Kotton, MD, FIDSA, FAST, will take you through a CMV primer and then move on to discuss cases submitted by your peers from transplant centers across the United States.

Credit Expired

0.75 CE Credit(s)

Expires: September 14, 2023

Target Audience

This activity is intended for clinicians practicing in transplantation, infectious disease, and nephrology.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Employ evidence-based antiviral treatment strategies for cytomegalovirus (CMV) in solid organ transplant (SOT) patients
Utilize antiviral resistance testing to identify SOT patients with treatment refractory or drug resistant CMV
Implement new treatment strategies in the management of resistant or refractory CMV in SOT patients

Activity Faculty

Camille Nelson Kotton, MD, FIDSA, FAST

Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Provider Statement

This activity is jointly provided by RMEI Medical Education, LLC and The Transplant Society.

Supporter Statement

Supported by an educational grant from Takeda.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 